It is well known that the development of a new drug is exorbitantly expensive and is a process which usually fails. Researchers at PrecisionLife posit that failure and the many patients with unmet treatment needs result from an over simplistic view of disease pathogeneses and an overreliance on a narrow range of target genes and pathways.

The eyes may be the window to the heart as well as the soul – particularly, to whether that heart is at risk of an infarct, researchers reported last week at the annual congress of the European Society of Human Genetics.

New treatments for cardiac hypertrophy, a thickening of the heart in response to pressure overload, could potentially treat or even reverse the condition after a new breakthrough discovery identified the mechanism that causes the heart's muscle to thicken, increasing the risk of irregular heart rhythms and heart failure.

At the European Hematology Association's annual meeting in Vienna last week, companies reported impressive progress for the treatment of sickle cell disease.

At the European Hematology Association’s annual meeting in Vienna last week, companies reported impressive progress for the treatment of sickle cell disease.

At the 2022 Annual Congress of the European Hematology Association, researchers from the Spanish National Cancer Institute reported how high levels of the RNA-binding protein hnRNP-K could lead to bone marrow failure.

A Massachusetts Institute of Technology-led team has identified distinct midbrain circuits that contributed to both motor and psychiatric symptoms of Parkinson's disease in animal models. Activating the circuits could reverse both types of symptoms.

A central assumption about so-called synonymous mutations, which are changes in the coding sequence of proteins that do not lead to changes in its amino acid sequence, is being questioned by a study published in the June 8, 2022, issue of Nature.

Researchers have identified a compound, ML-901, that showed highly specific and potent inhibition of the malaria parasite.